Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Development, Characterizations and Biocompatibility Evaluations of Intravitreal Lipid Implants

Lana Tamaddon 1 , Abolfazl Mostafavi 1 , * , Mohammad Riazi-esfahani 2 , Reza Karkhane 2 , Sara Aghazadeh 2 , Morteza Rafiee-Tehrani 3 , Farid Abedin Dorkoosh 3 and Fahimeh Asadi Amoli 2
Authors Information
1 Department of Pharmaceutics, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences,Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 3, 2014, 9 (2); e16414
  • Published Online: April 7, 2014
  • Article Type: Research Article
  • Received: November 26, 2013
  • Revised: December 7, 2013
  • Accepted: January 28, 2014
  • DOI: 10.17795/jjnpp-16414

To Cite: Tamaddon L, Mostafavi A, Riazi-esfahani M, Karkhane R, Aghazadeh S, et al. Development, Characterizations and Biocompatibility Evaluations of Intravitreal Lipid Implants, Jundishapur J Nat Pharm Prod. 2014 ; 9(2):e16414. doi: 10.17795/jjnpp-16414.

Abstract
Copyright © 2014, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2010; 99(5): 2219-39[DOI][PubMed]
  • 2. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001; 215(3): 143-55[PubMed]
  • 3. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 1996; 17(2): 93-102[PubMed]
  • 4. Guse C, Koennings S, Maschke A, Hacker M, Becker C, Schreiner S, et al. Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm. 2006; 314(2): 153-60[DOI][PubMed]
  • 5. Reitz C, Kleinebudde P. Solid lipid extrusion of sustained release dosage forms. Eur J Pharm Biopharm. 2007; 67(2): 440-8[DOI][PubMed]
  • 6. Vogelhuber W, Magni E, Mouro M, Spruss T, Guse C, Gazzaniga A, et al. Monolithic triglyceride matrices: a controlled-release system for proteins. Pharm Dev Technol. 2003; 8(1): 71-9[DOI][PubMed]
  • 7. Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(alpha-hydroxy esters). Pharm Res. 2002; 19(2): 175-81[PubMed]
  • 8. Koennings S, Sapin A, Blunk T, Menei P, Goepferich A. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J Control Release. 2007; 119(2): 163-72[DOI][PubMed]
  • 9. Reithmeier H, Herrmann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001; 73(2): 339-50
  • 10. Koennings S, Garcion E, Faisant N, Menei P, Benoit JP, Goepferich A. In vitro investigation of lipid implants as a controlled release system for interleukin-18. Int J Pharm. 2006; 314(2): 145-52[DOI][PubMed]
  • 11. Appel B, Maschke A, Weiser B, Sarhan H, Englert C, Angele P, et al. Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro. Int J Pharm. 2006; 314(2): 170-8[DOI][PubMed]
  • 12. Reithmeier H, Herrmann J, Gopferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int J Pharm. 2001; 218(1-2): 133-43[PubMed]
  • 13. Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007; 27(7): 952-7[DOI][PubMed]
  • 14. Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011; 118(1): 134-41[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments